Great Point Partners LLC Purchases Shares of 8,559,000 Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Posted by Grant Hamersma on Nov 27th, 2024

Great Point Partners LLC purchased a new stake in Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 8,559,000 shares of the company’s stock, valued at approximately $3,491,000. Unicycive Therapeutics makes up 1.0% of Great Point Partners LLC’s holdings, making the stock its 24th largest holding. Great Point Partners LLC owned 0.09% of Unicycive Therapeutics as of its most recent SEC filing.

Separately, Virtu Financial LLC acquired a new position in Unicycive Therapeutics in the first quarter valued at about $36,000. 40.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Benchmark restated a “speculative buy” rating and issued a $3.00 price target on shares of Unicycive Therapeutics in a research report on Friday, November 22nd. HC Wainwright restated a “buy” rating and issued a $2.50 price target on shares of Unicycive Therapeutics in a research report on Tuesday, November 12th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $5.13.

Check Out Our Latest Analysis on UNCY

Unicycive Therapeutics Trading Up 6.8 %

Shares of UNCY stock opened at $0.59 on Wednesday. Unicycive Therapeutics, Inc. has a 1 year low of $0.20 and a 1 year high of $1.82. The firm’s 50 day moving average is $0.45 and its 200-day moving average is $0.52.

Unicycive Therapeutics Profile

(Free Report)

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.